 Opiate Substitution Treatment
"Opiate Substitution Treatment" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Medical treatment for opioid dependence using a substitute opiate such as METHADONE or BUPRENORPHINE.
| Descriptor ID |
D058850
|
| MeSH Number(s) |
E02.319.620
|
| Concept/Terms |
Opiate Substitution Treatment- Opiate Substitution Treatment
- Opiate Substitution Treatments
- Substitution Treatment, Opiate
- Substitution Treatments, Opiate
- Treatment, Opiate Substitution
- Treatments, Opiate Substitution
- Opioid Substitution Treatment
- Opioid Substitution Treatments
- Substitution Treatment, Opioid
- Substitution Treatments, Opioid
- Treatment, Opioid Substitution
- Treatments, Opioid Substitution
- Opioid Substitution Therapy
- Opioid Substitution Therapies
- Substitution Therapies, Opioid
- Substitution Therapy, Opioid
- Therapies, Opioid Substitution
- Therapy, Opioid Substitution
- Opiate Replacement Therapy
- Opiate Replacement Therapies
- Replacement Therapies, Opiate
- Replacement Therapy, Opiate
- Therapies, Opiate Replacement
- Therapy, Opiate Replacement
- Opioid Replacement Therapy
- Opioid Replacement Therapies
- Replacement Therapies, Opioid
- Replacement Therapy, Opioid
- Therapies, Opioid Replacement
- Therapy, Opioid Replacement
|
Below are MeSH descriptors whose meaning is more general than "Opiate Substitution Treatment".
Below are MeSH descriptors whose meaning is more specific than "Opiate Substitution Treatment".
This graph shows the total number of publications written about "Opiate Substitution Treatment" by people in UAMS Profiles by year, and whether "Opiate Substitution Treatment" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2022 | 1 | 2 | 3 | | 2021 | 0 | 1 | 1 | | 2020 | 5 | 1 | 6 | | 2019 | 4 | 2 | 6 | | 2018 | 2 | 2 | 4 | | 2016 | 2 | 0 | 2 | | 2015 | 2 | 0 | 2 | | 2014 | 3 | 0 | 3 | | 2013 | 4 | 5 | 9 | | 2012 | 0 | 2 | 2 | | 2011 | 1 | 1 | 2 | | 2010 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Opiate Substitution Treatment" by people in Profiles over the past ten years.
-
Ali MM, Ghertner R. Is buprenorphine treatment availability associated with decreases in substantiated cases of child maltreatment? J Subst Abuse Treat. 2022 08; 139:108780.
-
Pro G, Hayes C, Brown CC, Goree J, Zaller N. Individual and Health Policy Factors Associated With Positive Heroin and Opioid Treatment Response: United States, 2018. Am J Public Health. 2022 02; 112(S1):S66-S76.
-
Hayes CJ, Cucciare MA, Martin BC, Hudson TJ, Bush K, Lo-Ciganic W, Yu H, Charron E, Gordon AJ. Using data science to improve outcomes for persons with opioid use disorder. Subst Abus. 2022; 43(1):956-963.
-
Lin LA, Fortney JC, Bohnert ASB, Coughlin LN, Zhang L, Piette JD. Comparing telemedicine to in-person buprenorphine treatment in U.S. veterans with opioid use disorder. J Subst Abuse Treat. 2022 02; 133:108492.
-
Zaller N, Brinkley-Rubinstein L. MOUD Provision in Correctional Settings During Time of COVID-19: Prevention and Solutions. J Addict Med. 2020 12; 14(6):e290-e292.
-
Ray-Griffith S, Tharp E, Coker JL, Catlin D, Knight B, Stowe ZN. Buprenorphine Medication for Opioid Use Disorder: A Study of Factors Associated With Postpartum Treatment Retention. Am J Addict. 2021 01; 30(1):43-48.
-
Pro G, Utter J, Haberstroh S, Baldwin JA. Dual mental health diagnoses predict the receipt of medication-assisted opioid treatment: Associations moderated by state Medicaid expansion status, race/ethnicity and gender, and year. Drug Alcohol Depend. 2020 04 01; 209:107952.
-
Pro G, Zaller N. Interaction effects in the association between methadone maintenance therapy and experiences of racial discrimination in U.S. healthcare settings. PLoS One. 2020; 15(2):e0228755.
-
Pro G, Utter J, Cram J, Baldwin J. Racial/Ethnic and Gender Differences in Associations of Medication-Assisted Therapy and Reduced Opioid Use between Outpatient Treatment Admission and Discharge. J Psychoactive Drugs. 2020 Apr-Jun; 52(2):186-194.
-
Peterson LE, Morgan ZJ, Borders TF. Practice Predictors of Buprenorphine Prescribing by Family Physicians. J Am Board Fam Med. 2020 Jan-Feb; 33(1):118-123.
-
Liu J, Shah SK, Basu-Ray I, Garcia-Diaz J, Khalid K, Saeed M. QT prolongation in HIV-positive patients: Review article. Indian Heart J. 2019 Nov - Dec; 71(6):434-439.
-
McClellan C, Fingar KR, Ali MM, Olesiuk WJ, Mutter R, Gibson TB. Price elasticity of demand for buprenorphine/naloxone prescriptions. J Subst Abuse Treat. 2019 11; 106:4-11.
-
Bolin EH, Escalona-Vargas D, Daily JA, Siegel ER, Lowery CL, Coker J, Stowe ZN, Eswaran H. Magnetocardiographic identification of prolonged fetal corrected QT interval in women receiving treatment for opioid use disorder. J Obstet Gynaecol Res. 2019 Oct; 45(10):1989-1996.
-
Derefinko KJ, Salgado García FI, Talley KM, Bursac Z, Johnson KC, Murphy JG, McDevitt-Murphy ME, Andrasik F, Sumrok DD. Adverse childhood experiences predict opioid relapse during treatment among rural adults. Addict Behav. 2019 09; 96:171-174.
-
Gressler LE, Shah S, Shaya FT. Association of Criminal Statutes for Opioid Use Disorder With Prevalence and Treatment Among Pregnant Women With Commercial Insurance in the United States. JAMA Netw Open. 2019 03 01; 2(3):e190338.
-
Wen H, Borders TF, Cummings JR. Trends In Buprenorphine Prescribing By Physician Specialty. Health Aff (Millwood). 2019 01; 38(1):24-28.
-
Coker JL, Catlin D, Ray-Griffith S, Knight B, Stowe ZN. Buprenorphine medication-assisted treatment during pregnancy: An exploratory factor analysis associated with adherence. Drug Alcohol Depend. 2018 11 01; 192:146-149.
-
Gressler LE, Titus-Glover D, Shaya FT. Treatment modalities for pregnant women with opioid use disorder. Lancet. 2018 08 18; 392(10147):551.
-
Brinkley-Rubinstein L, Zaller N, Martino S, Cloud DH, McCauley E, Heise A, Seal D. Criminal justice continuum for opioid users at risk of overdose. Addict Behav. 2018 11; 86:104-110.
-
Brinkley-Rubinstein L, McKenzie M, Macmadu A, Larney S, Zaller N, Dauria E, Rich J. A randomized, open label trial of methadone continuation versus forced withdrawal in a combined US prison and jail: Findings at 12 months post-release. Drug Alcohol Depend. 2018 03 01; 184:57-63.
-
Kumar N, Stowe ZN, Han X, Mancino MJ. Impact of early childhood trauma on retention and phase advancement in an outpatient buprenorphine treatment program. Am J Addict. 2016 10; 25(7):542-8.
-
Naeger S, Ali MM, Mutter R, Mark TL, Hughey L. Prescriptions Filled Following an Opioid-Related Hospitalization. Psychiatr Serv. 2016 11 01; 67(11):1262-1264.
-
Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C. Retention in medication-assisted treatment for opiate dependence: A systematic review. J Addict Dis. 2016; 35(1):22-35.
-
Rich JD, McKenzie M, Larney S, Wong JB, Tran L, Clarke J, Noska A, Reddy M, Zaller N. Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial. Lancet. 2015 Jul 25; 386(9991):350-9.
-
Zaller N, Mazhnaya A, Larney S, Islam Z, Shost A, Prokhorova T, Rybak N, Flanigan T. Geographic variability in HIV and injection drug use in Ukraine: implications for integration and expansion of drug treatment and HIV care. Int J Drug Policy. 2015 Jan; 26(1):37-42.
-
Christensen DR, Landes RD, Jackson L, Marsch LA, Mancino MJ, Chopra MP, Bickel WK. Adding an Internet-delivered treatment to an efficacious treatment package for opioid dependence. J Consult Clin Psychol. 2014 Dec; 82(6):964-72.
-
Rass O, Kleykamp BA, Vandrey RG, Bigelow GE, Leoutsakos JM, Stitzer ML, Strain EC, Copersino ML, Mintzer MZ. Cognitive performance in methadone maintenance patients: effects of time relative to dosing and maintenance dose level. Exp Clin Psychopharmacol. 2014 Jun; 22(3):248-256.
-
Rajpal S, Mundi AS, Reddy PC, Akkus NI. Treatment of methadone-induced torsades de pointes with lidocaine. J La State Med Soc. 2013 Nov-Dec; 165(6):338-41.
-
McClure EA, Acquavita SP, Dunn KE, Stoller KB, Stitzer ML. Characterizing smoking, cessation services, and quit interest across outpatient substance abuse treatment modalities. J Subst Abuse Treat. 2014 Feb; 46(2):194-201.
-
Sanders NC, Mancino MJ, Gentry WB, Guise JB, Bickel WK, Thostenson J, Oliveto AH. Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure. Exp Clin Psychopharmacol. 2013 Aug; 21(4):294-302.
-
Atkinson TS, Sanders N, Mancino M, Oliveto A. Effects of disulfiram on QTc interval in non-opioid-dependent and methadone-treated cocaine-dependent patients. J Addict Med. 2013 Jul-Aug; 7(4):243-8.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|